Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort.

Open forum infectious diseases·2026

Same author

Healthcare Resource Consumption and Related Costs of People Living with HIV and Antiviral Treatment: A Retrospective Observational Study in Italy.

Diseases (Basel, Switzerland)·2026

Same author

96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort study.

Journal of global antimicrobial resistance·2025

Same author

Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection.

AIDS (London, England)·2025

Same author

Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV.

The Journal of antimicrobial chemotherapy·2025

Same author

Adherence and Forgiveness of Two Modern ART Regimens: Lamivudine/Dolutegravir and Emtricitabine/Tenofovir Alafenamide/Rilpivirine.

Journal of acquired immune deficiency syndromes (1999)·2025

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Efavirenz.

Franco Maggiolo¹

¹Unit of Antiviral Therapy, Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy. franco31556@hotmail.com

Expert Opinion on Pharmacotherapy

|May 23, 2007

Summary

Efavirenz, a key HIV drug, offers effective treatment with a simple daily dose, improving patient adherence. While K103N mutations can occur, protease inhibitor-sparing regimens may reduce metabolic side effects.

Area of Science:

Virology
Pharmacology
Infectious Diseases

Background:

HIV treatment typically involves multi-drug regimens.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
NNRTIs non-competitively inhibit viral enzymes.

Purpose of the Study:

To review the efficacy and tolerability of efavirenz-based HIV therapies.
To discuss efavirenz's role in treatment-naive and pretreated patients.
To highlight the benefits of protease inhibitor-sparing regimens.

Main Methods:

Review of clinical data and studies on efavirenz regimens.
Analysis of efavirenz's mechanism of action and resistance patterns.
Comparison of efavirenz-based therapy with protease inhibitor-based therapies.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jul 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Main Results:

Efavirenz-based regimens show favorable outcomes compared to protease inhibitors.
Once-daily dosing enhances adherence and treatment durability.
K103N is the most frequent efavirenz-selected mutation during viral rebound.

Conclusions:

Efavirenz is an effective component of HIV treatment regimens.
Simple dosing improves patient adherence and long-term response.
Protease inhibitor-sparing strategies may mitigate metabolic adverse events.